FDA approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with pheochromocytoma or paraganglioma that cannot be surgically removed, have spread beyond the original tumor site and require systemic anticancer therapy.
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
